-sensing domain of STIM1 with the 12-kDa FK506-and rapamycin-binding protein (FKBP12, also known as FKBP1A) or the FKBP-rapamycin binding (FRB) domain of the mammalian target of rapamycin (mTOR, also known as FRAP1). A rapamycin analogue oligomerizes the fusion proteins and causes them to accumulate at ER-PM junctions and activate CRAC channels without depleting Ca 21 from the ER. Thus, STIM1 oligomerization is the critical transduction event through which Ca 21 store depletion controls store-operated Ca 21 entry, acting as a switch that triggers the self-organization and activation of STIM1-ORAI1 clusters at ER-PM junctions.
] ER in the range of ,1 mM to .1 mM (Supplementary Fig. 2 ).
To determine the dependence of CRAC channel activation on [Ca 21 ] ER , we measured CRAC current (I CRAC ) in perforated-patch 1 ] ER (middle) monitored with YC4.2er. The current-voltage (I-V) relationship shows the inward rectification typical of I CRAC (bottom). In this cell, a small inward current through outwardly rectifying Cl 2 channels is also present initially but disappears before I CRAC is induced. Extracellular [Ca 21 ] in mM is indicated above the bars in a and b. b, Recordings of I CRAC (top) and [Ca 21 ] ER (middle) under steady-state conditions. Each cell was treated with the indicated CPA concentration for 8-15 min before recording, and CPA was maintained throughout the experiment. I-V relationships are typical for I CRAC (bottom). c, Steadystate I CRAC and [Ca recordings from Jurkat YC4.2er cells treated with cyclopiazonic acid (CPA), a reversible SERCA (sarco/endoplasmic reticulum Ca 21 -ATPase) inhibitor. CPA evokes a time-dependent decline in [Ca 21 ] ER in parallel with the activation of I CRAC measured in the same cell (Fig. 1a) (Fig. 1b) . The current was identified as I CRAC on the basis of its inwardly rectifying current-voltage relationship , extremely low current noise, and a delayed response to extracellular Ca 21 resulting from Ca 21 -dependent potentiation (Fig. 1b) 1 6, 7 and its redistribution to ER-PM junctions is linked to I CRAC activation [6] [7] [8] 11 , we measured the dependence of STIM1 redistribution on [Ca 21 ] ER . Exposure to 0.5-3 mM CPA for .8 min causes a partial redistribution of Cherry-STIM1 to the cell periphery, which can be seen by wide-field imaging at the cell equator (Fig. 2a) . We quantified the redistribution of Cherry-STIM1 as the ratio of the mean peripheral fluorescence to the mean total fluorescence (Fig. 2b) ; this method gives results that agree quantitatively with total internal reflection fluorescence (TIRF) measurements of STIM1 puncta ( Supplementary Fig. 3 ) while facilitating the separation of the cameleon and Cherry fluorescence signals (see Supplementary Information). Measurements from 41 cells show that STIM1 redistribution is a steep function of [Ca 21 ] ER that closely resembles that of I CRAC activation, with a K 1/2 of 187 mM and a Hill coefficient of 3.8 (Fig. 2c) ] ER implies that in Jurkat cells STIM2 activates at most a minor fraction of endogenous CRAC channels, consistent with its low level of expression in T cells 15 . The shape of the STIM1 redistribution curve has important implications for the mechanism underlying SOCE. The Hill coefficient of ,4 shows that puncta formation is a nonlinear process with respect to [Ca 21 ] ER , without necessarily indicating a cooperative mechanism or that the active form of STIM1 is a tetramer. However, the high Hill coefficient implies that STIM1 puncta at ER-PM junctions do not form by the independent accretion of STIM1 monomers, which contain only a single luminal Ca 21 -binding site 5 , but suggests instead that only oligomers of STIM1 can accumulate at these sites. There are two ways in which STIM1 is known to oligomerize. In resting cells, STIM1 self-associates with an undetermined stoichiometry by means of its cytosolic coiled-coil domains 16, 17 ; in addition, removal of Ca 21 from the EF-hand of STIM1 drives further oligomerization in vitro 5 and in vivo 4 . Store-dependent oligomerization of STIM1 occurs within seconds, slightly in advance of puncta formation, and a causal role in SOCE has been hypothesized but never tested 4, 5 . To address the possible role of STIM1 oligomerization in SOCE, we adopted an approach based on rapamycin-induced protein heterodimerization 18, 19 . We replaced the luminal region of Cherry-STIM1 (containing the EF-hand and SAM domains) with a tandem dimer of FK506-binding protein (FKBP12) or a variant of the FKBPrapamycin binding domain of mTOR (FRB) to generate STIM1 chimaeras that will heterodimerize when bound to a rapamycin analogue (AP21967, or rapalogue). Given that STIM1 is known to selfassociate at rest 16, 17 , rapalogue would thus be expected to link multimers containing FRB with those containing FKBP to form extended oligomers of STIM1 (Fig. 3a) . We assayed oligomer formation in HEK293 cells expressing Cherry-FRB-STIM1 and Cherry-FKBP-STIM1 (abbreviated hereafter as F-STIM1) using blue native polyacrylamide gel electrophoresis (BN-PAGE) 20 . The .2-fold increase in apparent mass after rapalogue treatment confirms its ability to oligomerize F-STIM1, and because crosslinking of monomers would be expected to at most double the mass, indicates that the resting state of FRB-STIM1 and FKBP-STIM1 is at least a dimer (Fig. 3b) .
We first examined the effects of rapalogue on the localization of F-STIM1 in Jurkat cells. Rapalogue evoked a redistribution of F-STIM1 to the cell periphery that was complete within several minutes (Fig. 3c ). Quantitative analysis shows that rapalogue triggers the redistribution of F-STIM1 as effectively as Ca 21 -store depletion induces the redistribution of wild-type STIM1 (Fig. 3d) . When examined by TIRF microscopy, the rapalogue-driven peripheral accumulations of F-STIM1 (Fig. 3e ) resemble the puncta of wild-type STIM1 that form in response to store depletion (Fig. 3f) . Similar results were obtained in HEK293 cells. Rapalogue did not affect the localization of wild-type STIM1 (Fig. 3g) , nor did it deplete Ca 21 stores (see below). Finally, rapalogue-induced F-STIM1 puncta co-localize with storedepletion-induced green fluorescent protein (GFP)-STIM1 puncta in the same cell, confirming that rapalogue causes F-STIM1 to accumulate at the same ER-PM junctions where STIM1 and ORAI1 are known to interact. Thus, we conclude that oligomerization of STIM1 is sufficient to drive the redistribution of STIM1 to ER-PM junctions.
Heterodimerization of FRB-STIM1 and FKBP-STIM1 also activates endogenous CRAC channels. Rapalogue increased the mean resting [Ca 21 ] i in Jurkat cells expressing F-STIM1 (Cherry-positive cells) from 170 6 11 nM (untreated; n 5 61) to 388 6 45 nM ( Fig. 4a ] pipette solution designed to minimize store depletion confirmed that heterodimerization of FRB-STIM1 and FKBP-STIM1 directly activates I CRAC . In untreated Jurkat cells expressing F-STIM1, I CRAC was negligible on breaking in to the whole-cell recording configuration and developed slowly to a small amplitude, presumably in response to partial store depletion. In contrast, in rapamycin-pretreated cells with visible puncta, large inward currents were evident immediately on breaking in (Fig. 4b ) and displayed essential features of I CRAC , including a dependence on extracellular Ca 21 , an inwardly rectifying current-voltage relationship (Fig. 4c) , low current noise, rapid Ca 21 -dependent inactivation, and inhibition by 2-APB and La 31 ( Supplementary Fig. 4 ) 13 . The mean current amplitude (2.6 6 0.6 pA pF 21 , n 5 9) was similar to that produced by Ca 21 ] ER , and that oligomerization of F-STIM1 is sufficient to drive puncta formation and CRAC channel activation. These results define the input-output relationship of the CRAC channel and identify STIM1 oligomerization as the primary transduction event through which this relationship is determined. The EF hand and SAM domains of STIM1 seem to serve primarily to control the extent of oligomerization, considering that removal of Ca 21 causes a recombinant EF-SAM peptide to oligomerize in vitro 5 , and that the FRB and FKBP modules in F-STIM1 can effectively substitute for the EF-hand and SAM domains and activate I CRAC when crosslinked by rapalogue. The fact that the latter occurs without Ca 21 store depletion suggests that once STIM1 oligomerizes, all subsequent steps leading to SOCE occur independently of ER Ca 21 . Thus, we propose that the oligomerization of STIM1 acts as a switch to trigger the self-organization of STIM1 and ORAI1 complexes at ER-PM junctions and the consequent activation of CRAC channels.
How might this oligomerization 'switch' operate? In its resting state Ca 21 -bound STIM1 moves freely throughout the ER membrane 4 , but after store depletion STIM1 oligomers accumulate in ER subregions located 10-25 nm from the PM, close enough to allow trapping by binding to targets in the PM 8 . These targets have not yet been positively identified, but suggested candidates include ORAI1 (refs 21, 22) or an associated protein 23 , as well as PM phospholipids 4, 24 . Once localized at ER-PM junctions, STIM1 then promotes the accumulation of ORAI1 at apposed sites, leading to channel activation 11, 12, 25 . Oligomerization may promote the binding of STIM1 to its targets in two ways: an affinity-based mechanism in which a conformational change exposes a previously masked cytosolic binding domain, and an avidity-based mechanism in which clustering of the binding domains increases their local concentration at ER-PM junctions. Both of these mechanisms are likely to contribute to the assembly and function of CRAC channel complexes that constitute the final stage of the store-operated Ca 21 entry process. -free Ringer's solution for 8-15 min, and emission intensities at 485 nm and 535 nm were averaged across the cell to yield a raw emission ratio. Ratios were calibrated in situ for every cell as described (Supplementary Information). Heterodimerizer experiments. To generate F-STIM1, mutant FRB and tandem FKBP sequences were substituted for the EF-SAM domain (wild-type STIM1, amino acids 35-207) in Cherry-STIM1 using plasmids provided by Ariad Pharmaceuticals. F-STIM1 was crosslinked using 1 mM rapalogue (AP21967, Ariad Pharmaceuticals). Unless indicated otherwise, cells were pre-incubated in full medium at 37 uC for 30 min, with or without rapalogue, and subsequent measurements were performed at 22-25 uC in standard Ringer's solutions. Time-lapse imaging was performed at 37 uC in full medium with or without rapalogue. Only cells with ,3-10% of the fluorescence of the brightest cells in each experiment were analysed. BN-PAGE was performed essentially as described 20 . A monoclonal antibody against the STIM1 carboxy terminus (1:250; Abnova) and an alkaline-phosphatase-conjugated secondary antibody (1:30,000; Sigma) were used for western blotting. Perforated-patch and whole-cell recording. I CRAC in YC4.2er cells (Fig. 1) was recorded in the perforated-patch configuration 29 with 20 mM extracellular Ca 21 , using a stimulus of a 50-ms step to -100 mV followed by a ramp from -100 to 1100 mV, delivered from a holding potential of 130 or 150 mV. Whole-cell recording of I CRAC (ref. 30 ; Fig. 4 ) was performed with 20 mM Ca 21 Ringer's solution, with stimuli consisting of a 100-ms step to 2112 mV followed by a 100-ms voltage ramp from -112 to 188 mV applied from the holding potential of 138 mV beginning within 5 s of break-in. 
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and Jurkat YC4.2er cell lines were maintained as described previously 31 . Unless indicated otherwise, experiments were performed at 22-25 uC after cells were attached to poly-D-lysine-coated coverslip chambers and were bathed in Ringer's solution containing (in mM): 155 NaCl, 4.5 KCl, 2 or 20 CaCl 2 , 1 MgCl 2 , 10 D-glucose and 5 Na-HEPES (pH 7.4). For Ca 21 -free Ringer's solution, CaCl 2 was replaced with 1 mM EGTA plus 2 mM MgCl 2 . To deplete Ca 21 stores, cells were exposed to Ca 21 -free Ringer's solution supplemented with CPA (0.5-20 mM) or thapsigargin (1 mM). All salts and chemicals were from Sigma unless otherwise stated. Thapsigargin was purchased from LC Laboratories, ionomycin and digitonin were from EMD Biosciences, Inc., monoclonal antibody OKT3 was from eBioscience and Fura-2/AM and Mitotracker Red were purchased from Invitrogen. AP21967 (rapalogue) was provided by Ariad Pharmaceuticals (www.ariad.com/regulationkits). Plasmids and transfection. Point mutations V68L and Q69M were introduced into the original YC4er (provided by R. Tsien) to generate YC4.2er (refs 26-28) . Jurkat E6-1 cells were transfected with YC4.2er by electroporation and selected for stable expression with G418. A monoclonal line with the highest cameleon expression and normal SOCE was used. Construction of Cherry-STIM1 and GFP-myc-ORAI1 were described previously 11 . For the construction of F-STIM1, mutant FRB (pC 4 -R H E) and tandem FKBP (pC 4 M-F2E) plasmids were provided by Ariad Pharmaceuticals. The provided variant of FRB binds an analogue of rapamycin (AP21976, or rapalogue) that fails to bind native mTOR, enabling heterodimerization of FRB and FKBP while avoiding potential side effects from inhibition of mTOR kinase activity 18 . FRBand tandem FKBP-containing STIM1 plasmids were made by engineering two unique restriction sites, a NheI site after Cherry and a MluI site after the SAM domain, into Cherry-STIM1 using site-directed mutagenesis (Quikchange XL, Stratagene). The plasmid was then digested with NheI and MluI to remove the EF-hand and SAM domains (amino acids 35-207 in the wild-type STIM1 sequence). FRB was amplified from pC 4 -R H E using the primers (59-39) TGATTAGCTAGCGGTGCTGGTGCTGGTGCTGGTGCTGGTGCTGGTAT-CCTCTGGCATGAG and (59-39) CGACGAATCTCAAAGGGAGCAGGAGC AGGAGCAGGAGCAGGAGCAGGAACGCGTGTAATT to append 11 amino acid linkers (GAGAGAGAGAG) flanked by NheI or MluI restriction sites, respectively. Tandem FKBP (23FKBP) was amplified from pC 4 M-F2E using the primers (59-39) TGATTAGCTAGCGGTGCTGGTGCTGGTGCTGGTG CTGGTGCTGGTGGAGTGCAGGTGGAA and (59-39) CTGCTGAAGCTGG AGGGAGCAGGAGCAGGAGCAGGAGCAGGAGCAGGAACGCGTGTAATT. Amplified, the FRB and 23FKBP were separately ligated into NheI-and MluIdigested Cherry-STIM1. The introduction of the NheI site introduced a premature STOP codon, which was removed by site-directed mutagenesis.
FRB-STIM1 and FKBP-STIM1 were transiently transfected into Jurkat E6-1 or Jurkat YC4.2er cells by electroporation as described 8 , or into HEK293 cells by lipofection following the manufacturer's protocol (Invitrogen) using 0.5 mg of each construct. Cells were studied 48-72 h after transfection. Fluorescence microscopy. Wide-field epifluorescence and TIRF microscopy was performed essentially as described using a Zeiss Axiovert 200M microscope 8 . For wide-field epifluorescence microscopy of YC4.2er, cells were excited at 420 nm and dual emission ratios were collected using a 455 DCLP filter cube (Chroma) and by rapidly alternating D485/40 and D535/30 emission filters with a filter changer (Lambda 10-2, Sutter Instruments) positioned at the exit port of the microscope. All images were acquired with a cooled CCD camera (ORCA-ER, Hamamatsu) using 2 3 2 binning (GFP, Cherry, YC4.2er) or 4 3 4 binning (YC4.2er when co-expressed with Cherry). Fluorescence resonance energy transfer measurements of [Ca 21 ] ER . Background-corrected emission intensities at 535 nm and 485 nm were averaged across the cell to yield a raw F 535 /F 485 emission ratio. At the end of every experiment, in situ calibration of YC4.2er cells was performed by adding digitonin (50-75 mg ml
21
) and ionomycin (10 mM) to permeabilize the plasma membrane while leaving intracellular organelles intact and to equilibrate Ca 21 across the ER membrane (Supplementary Fig. 2 ). In the presence of ionomycin and digitonin, two standard F 535 /F 485 ratios (R 1 and R 2 ) were obtained after exposing the cells to (in mM): 75 K aspartate, 60 KCl, 1 MgCl 2 , and either 10 EGTA (for R 1 ) or 20 CaCl 2 (for R 2 ). For every cell, raw F 535 /F 485 ratios (R) were normalized using these standard solutions:
where R norm is the normalized YC4.2er ratio 27 . R norm was converted to [Ca 21 ] ER using a calibration curve determined separately.
A complete calibration curve for YC4.2er (Supplementary Fig. 2) (Supplementary Fig. 2b ). Thus, in the few cells where R norm fell below the R min for this low-affinity binding site, [Ca 21 ] ER was assigned a value of 400 nM. Immunocytochemistry. Jurkat YC4.2er cells were attached to poly-D-lysinecoated glass coverslips and fixed in 4% fresh paraformaldehyde at 22-25 uC for 15 min. For staining with polyclonal anti-calnexin antibody (Stressgen Biotechnologies Corp.), cells were permeabilized for 5 min in cold methanol at -20 uC. For staining with monoclonal anti-golgin-97 (Molecular Probes), cells were permeabilized in 0.5% Triton X-100 in phosphate-buffered saline containing 0.2% bovine serum albumin (PBS/BSA) for 5 min at 22-25 uC. After permeabilization, cells were rinsed three times with PBS and incubated in blocking buffer containing 20 mM glycine, 75 mM NH 4 Cl, 0.2% BSA and 1% goat serum in PBS for 1 h. Cells were then incubated with primary antibodies (1:1,000 dilution in blocking buffer) for an additional 1 h and rinsed three times with blocking buffer to remove unbound antibody. Alexa 594-conjugated secondary antibody (Molecular Probes; 1:1,000 dilution in PBS/BSA) was applied for 45 min, followed by three rinses with PBS/BSA. Coverslips were mounted in Vectashield (Vector Laboratories) and viewed with a Zeiss Axiovert 200M microscope (340 NA1.3 oil), or a Molecular Dynamics Multiprobes 2010 confocal microscope (340 NA1.3 oil). Quantification of STIM1 redistribution. A binary mask of the cell periphery was applied to each background-corrected Cherry image by drawing a polygonal region with a width of 0.5 mm around the edge of the cell. The extent of Cherry redistribution was assessed as the mean intensity within the masked region (F P ) divided by the intensity averaged across the whole cell (F TOT ). In TIRF experiments, background-corrected Cherry images were thresholded to exclude remaining background fluorescence, and intensity was measured within an outline drawn around the cell footprint in the first frame of each time-lapse series. To compensate for any cell-to-cell differences in the abundance of peripheral ER, changes in redistribution measured by TIRF or wide-field epifluorescence microscopy were normalized to the maximal response obtained in each cell after store depletion with thapsigargin. Mean values of normalized F P /F TOT or TIRF intensities were calculated from 3-4 images for each data point. Heterodimerizer experiments. All experiments were performed using 1 mM AP21967. For time-lapse imaging of F-STIM1 redistribution in response to AP21967, cells were imaged using wide-field epifluorescence at 37 uC in full medium. TIRF measurements of F-STIM1 were made at 22-25 uC in 2 mM Ca 21 Ringer's solution, before and after treatment with AP21967 for 30 min in full medium at 37 uC on the microscope stage; untreated cells were incubated in full medium alone under the same conditions. Otherwise, cells were pretreated for 30 min in full medium with (treated cells) or without (untreated cells) AP21967 at 37 uC in a CO 2 incubator before imaging at 22-25 uC. Cells overexpressing STIM1 or F-STIM1 at high levels often displayed puncta in the resting state, and correspondingly increased resting [Ca 21 ] i . This effect of overexpression has also been reported by others for STIM1 (ref. 7) . To avoid these effects of overexpression, we restricted analysis to cells with ,3-10% of the fluorescence of the brightest cells in each experiment. BN-PAGE and western blot analysis. BN-PAGE was performed using the NativePAGE Novex Bis-Tris gel system (Invitrogen) according to the manufacturer's instructions. In brief, 10 7 HEK293 cells expressing F-STIM1 were solubilized using NativePAGE sample buffer supplemented with 1% n-dodecyl-b-Dmaltoside. For the rapalogue condition, cells were incubated with 1 mM AP21967 for 30 min at 37 uC before solubilization, and 1 mM AP21967 was included in the sample buffer. Coomassie G-250 was added to samples, and 0.5-1% of the sample was loaded onto the NativePAGE Novex 4-16% Bis-Tris gel. Proteins bound to Coomassie G-250 were transferred electrophoretically to Hybond-P membrane (GE Healthcare) in Tris/Glycine buffer (BioRad) for 14 h at 60 mA,
